Semaglutide, marketed as Ozempic and Wegovy for injection or Rybelsus as an oral tablet, is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes and chronic weight management
In some cases, it is recommended to inject once a week
The FDA schedule keeps patients at 0.25 mg for four weeks, then 0.5 mg, to limit GI side effects while the body adjusts to the medication
one of three biosimilars to rituximab (Rituxan) New indication: moderate to severe PV in adults Administered as two IV infusions separated by two weeks in combination with a tapering course of glucocorticoids, then a subsequent maintenance IV infusion at month 12 and every six months thereafter or based on clinical evaluation
The most common side effects of receiving ACTRAPID 100IU INJECTION are low blood sugar levels, pain, redness, itching, swelling or thickening at the injection site, lump formation under the skin and swelling of body parts